How many drugs treat Chlamydial pneumonia?

Drug Landscape tracks 10 marketed treatments for Chlamydial pneumonia (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/chlamydial-pneumonia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Chlamydial pneumonia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chlamydial pneumonia (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Chlamydial pneumonia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Ketek	TELITHROMYCIN	Sanofi	Ketolide Antibacterial	Potassium voltage-gated channel subfamily H member 2	2004-01-01
Factive	GEMIFLOXACIN MESYLATE	Lg Chem Ltd	Quinolone Antimicrobial		2003-01-01
Factive	GEMIFLOXACIN	Lg Chem Ltd	Quinolone Antimicrobial		2003-01-01
Zymar	GATIFLOXACIN	Allergan		DNA gyrase, DNA gyrase, DNA gyrase subunit A	2003-01-01
Avelox	moxifloxacin	Bayer AG	Fluoroquinolone antibiotic (fourth-generation)	DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A	1999-12-10
ALATROFLOXACIN	ALATROFLOXACIN	Pfizer	alatrofloxacin		1997-01-01
Levaquin	levofloxacin	Generic (originally Daiichi Sankyo/J&J)	Fluoroquinolone Antibacterial [EPC]	CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2	1996-12-20
Zithromax	azithromycin	Pfizer Inc.	Macrolide antibiotic (azalide)	Canalicular multispecific organic anion transporter 1, Taste receptor type 2 member 4, Motilin receptor	1991-11-01
Biaxin	clarithromycin	Generic (originally Abbott/AbbVie)	Macrolide Antimicrobial [EPC]	Potassium voltage-gated channel subfamily H member 2	1991-10-31
Benzamycin	Erythromycin Lactobionate	Pfizer	Macrolide	Potassium voltage-gated channel subfamily H member 2	1964-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 3 drugs in Chlamydial pneumonia
Pfizer · 2 drugs in Chlamydial pneumonia
Lg Chem Ltd · 2 drugs in Chlamydial pneumonia
Bayer AG · 1 drug in Chlamydial pneumonia
Generic (originally Abbott/AbbVie) · 1 drug in Chlamydial pneumonia
Generic (originally Abbott/Lilly) · 1 drug in Chlamydial pneumonia
Generic (originally Daiichi Sankyo/J&J) · 1 drug in Chlamydial pneumonia
Novartis Pharmaceuticals · 1 drug in Chlamydial pneumonia
Pfizer Inc. · 1 drug in Chlamydial pneumonia
Sanofi · 1 drug in Chlamydial pneumonia
Allergan · 1 drug in Chlamydial pneumonia
Assistance Publique - Hôpitaux de Paris · 1 drug in Chlamydial pneumonia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Chlamydial pneumonia:

Cite this brief

Drug Landscape (2026). Chlamydial pneumonia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/chlamydial-pneumonia. Accessed 2026-06-10.

Chlamydial pneumonia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing